Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lu...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

stny Aug. 28 at 6:49 PM

$INBX

0 · Reply

CapitalMonk Aug. 26 at 10:04 PM

$INBX Price: $125.34 (+2.13%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±5.34% RSI: 80.1 | Momentum: Strong Momentum Volume: +15.1% vs avg Volatility: 5.14% Support: $79.67 | Resistance: $131.01 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai

0 · Reply

BullStockpicks1 Aug. 26 at 6:00 AM

$INBX - tried to let you all know. The crazy thing is this is extremely low still here. With the 106 results coming I see a run to $200 range. Remember 109 is with $150-200 on its own before CRC data, with it probably $350-$450. 106 is a $8-10B drug $400-500 with CVR so all in we are looking at $750+ by end of 2027. This is a tremendous opportunity

1 · Reply

LivermoresGhost Aug. 26 at 4:20 AM

$CVAT $CVAT BUYOUT ALERT: Cavitation Technologies CVAT has execute a buyout for this company at 35 million $. This translate to 11.2c per share, you can finds this on the company SEC filing. The stock right now trades 4.3c, the buyout is for 11.2c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 11.2c Current sp: 4.3c 270% Return on Investment, Tender will start this week!!!!!!!!!!!! https://in.investing.com/news/stock-market-news/cavitation-technologies-agrees-to-35-million-acquisition-deal-93CH-5559884 Here is the company thats buying Cavitation, they have 20 billion Euros Capital Backing. https://euroguarantee.lu/ $BRNX $INBX $MEI $BOXL

0 · Reply

Terzman Aug. 25 at 11:07 PM

$INBX seems to me very very very little paper .. shorts seem like they starting to realize that ..

0 · Reply

MBWallingford Aug. 25 at 10:42 PM

$INBX feels like something is brewing but hard to tell. Buyout or something positive in the drug trials? Dont know. A lot of times they turn out to nothing. Zero news. Buyouts typically happen on Merger Mondays. Volume is better than normal but still pretty light. Just letting it ride for now. Too much risk to buy anymore. Wonder if the fool top stock alerts is posting because of the price change. He just wants to get paid for his worthless advice.

2 · Reply

topstockalerts Aug. 25 at 8:41 PM

$INBX this stock is acting like it has somewhere to be

0 · Reply

kundakunda Aug. 25 at 7:37 PM

$INBX is this a buyout info leaking somewhere? Can't find any other info, just an analyst upgrade

2 · Reply

Dmnaz Aug. 25 at 7:26 PM

$INBX look at the number of watchers. 777. Good fortune

0 · Reply

TrendTrade8696 Aug. 25 at 6:56 PM

$INBX INBX shows a major technical breakout supported by strong volume, bullish momentum indicators (Bollinger Bands, MACD, Money Flow) and price strength above both key moving averages. The stock also has a tight effective float due to insider and institutional ownership, plus several new 5%+ holders accumulating shares. With 3.3–3.5M shares short (roughly 28–31% of float), demand could exceed available supply if buyers continue stepping in and large holders keep holding.The technical breakout + limited supply already created a strong setup. A short squeeze, if it develops, would potentially become an additional accelerator. GO INBX!!

0 · Reply

Inhibrx initiated with a Buy at H.C. Wainwright

Aug 13, 2026, 4:04 PM EDT - 16 days ago

Inhibrx Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 7:00 AM EDT - 17 days ago

Inhibrx Biosciences Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 17 days ago

Inhibrx Biosciences Earnings release: Q2 2026

Jul 16, 2026, 9:00 AM EDT - 6 weeks ago

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

2026-06-15T13:30:13.000Z - 2 months ago

Inhibrx announces FDA acceptance of BLA for ozekibart

Jun 15, 2026, 9:15 AM EDT - 2 months ago

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

2026-05-15T13:15:11.000Z - 3 months ago

Inhibrx price target raised to $325 from $300 at Stifel

May 14, 2026, 4:02 PM EDT - 3 months ago

Inhibrx Reports First Quarter 2026 Financial Results

May 14, 2026, 7:00 AM EDT - 3 months ago

Inhibrx Biosciences Quarterly report: Q1 2026

2026-05-11T16:20:41.000Z - 3 months ago

Inhibrx’s INBRX-106 shows potential benefit in HNSCC

May 11, 2026, 8:30 AM EDT - 3 months ago

Inhibrx Biosciences Transcript: Study update

May 11, 2026, 8:30 AM EDT - 3 months ago

Inhibrx Biosciences Press release: Study update

May 11, 2026, 8:26 AM EDT - 3 months ago

This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know.

May 11, 2026, 8:00 AM EDT - 3 months ago

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy

May 8, 2026, 4:00 PM EDT - 4 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC

2026-04-24T13:35:38.000Z - 4 months ago

Inhibrx initiated with an Outperform at LifeSci Capital

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Inhibrx Biosciences Proxy statement: Proxy filing

2026-04-22T16:50:17.000Z - 4 months ago

Inhibrx price target raised to $300 from $150 at Stifel

2026-04-22T14:07:06.000Z - 4 months ago

Inhibrx trading halted, volatility trading pause

2026-04-22T14:01:35.000Z - 4 months ago

Inhibrx trading resumes

2026-04-22T12:50:13.000Z - 4 months ago

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

MRK

2026-04-22T12:49:00.000Z - 4 months ago

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

Apr 22, 2026, 7:02 AM EDT - 4 months ago

Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

MRK

Apr 21, 2026, 4:30 PM EDT - 4 months ago

Inhibrx Biosciences Transcript: Study update

Apr 21, 2026, 4:30 PM EDT - 4 months ago

Inhibrx Biosciences Press release: Study update

2026-04-21T20:24:03.000Z - 4 months ago

Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart

Apr 21, 2026, 4:05 PM EDT - 4 months ago

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Apr 21, 2026, 7:00 AM EDT - 4 months ago

Inhibrx Biosciences Slides: Investor presentation

Apr 20, 2026, 5:03 PM EDT - 4 months ago

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

2026-04-07T20:17:46.000Z - 5 months ago

Inhibrx initiated with a Buy at Stifel

Mar 19, 2026, 6:00 PM EDT - 5 months ago

Inhibrx Biosciences Earnings release: Q4 2025

Mar 19, 2026, 6:00 PM EDT - 5 months ago

Inhibrx Biosciences Annual report: Q4 2025

2026-03-19T20:10:58.000Z - 5 months ago

Inhibrx reports Q4 EPS ($2.11) vs. ($3.09) last year

Mar 19, 2026, 4:00 PM EDT - 5 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Mar 12, 2026, 7:00 AM EDT - 6 months ago

Inhibrx Biosciences Slides: Investor presentation

Mar 2, 2026, 4:00 PM EST - 6 months ago

Inhibrx Announces Participation in Upcoming Scientific Conference

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE KOD LITE

2025-12-16T22:10:33.000Z - 9 months ago

Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial

Dec 16, 2025, 5:00 PM EST - 9 months ago

Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program

Nov 14, 2025, 6:00 AM EST - 10 months ago

Inhibrx Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 6:00 PM EST - 10 months ago

Inhibrx Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 6:00 PM EST - 10 months ago

Inhibrx Biosciences Earnings release: Q3 2025

Nov 4, 2025, 4:01 PM EST - 10 months ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Oct 23, 2025, 6:39 PM EDT - 11 months ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 4:30 PM EDT - 11 months ago

Inhibrx Biosciences Transcript: Study Result

Oct 23, 2025, 4:30 PM EDT - 11 months ago

Inhibrx Biosciences Press release: Study Result

Oct 23, 2025, 4:05 PM EDT - 11 months ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 11 months ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q2 2025

May 14, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Quarterly report: Q1 2025

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Inhibrx Biosciences Proxy statement: Proxy filing

Apr 1, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Earnings release: Q4 2024

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Inhibrx Biosciences Annual report: Q4 2024

Jan 21, 2025, 5:01 PM EST - 1 year ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 1 year ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 1 year ago

Inhibrx Biosciences Quarterly report: Q3 2024

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 13, 2024, 6:54 PM EDT - 2 years ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Aug 13, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Quarterly report: Q2 2024

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Registration statement: Registration filing

May 24, 2024, 4:00 PM EDT - 2 years ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 21, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 17, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

May 10, 2024, 6:36 PM EDT - 2 years ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 2 years ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 2 years ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 12, 2024, 8:00 AM EDT - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Feb 28, 2024, 9:15 AM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Feb 28, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Annual report: Q4 2023

Feb 6, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 11:45 AM EST - 2 years ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 7:00 AM EST - 2 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Jan 23, 2024, 5:39 AM EST - 2 years ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 2 years ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 2 years ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 2 years ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 3 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Sep 19, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 3 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 7, 2023, 4:00 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 3 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 3 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Inhibrx Biosciences Proxy statement: Proxy Filing

Mar 6, 2023, 4:05 PM EST - 3 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

stny Aug. 28 at 6:49 PM

$INBX

0 · Reply

CapitalMonk Aug. 26 at 10:04 PM

0 · Reply

BullStockpicks1 Aug. 26 at 6:00 AM

1 · Reply

LivermoresGhost Aug. 26 at 4:20 AM

0 · Reply

Terzman Aug. 25 at 11:07 PM

$INBX seems to me very very very little paper .. shorts seem like they starting to realize that ..

0 · Reply

MBWallingford Aug. 25 at 10:42 PM

2 · Reply

topstockalerts Aug. 25 at 8:41 PM

$INBX this stock is acting like it has somewhere to be

0 · Reply

kundakunda Aug. 25 at 7:37 PM

$INBX is this a buyout info leaking somewhere? Can't find any other info, just an analyst upgrade

2 · Reply

Dmnaz Aug. 25 at 7:26 PM

$INBX look at the number of watchers. 777. Good fortune

0 · Reply

TrendTrade8696 Aug. 25 at 6:56 PM

0 · Reply

ProbablyWrongAgain Aug. 25 at 6:43 PM

$INBX still

0 · Reply

judgeyoung2 Aug. 25 at 5:13 PM

$INBX well the lottos I got for the readout are already in the money 😅

1 · Reply

Mike22332233 Aug. 25 at 4:58 PM

$SLS $INBX $MRK Just like I said 2 weeks ago !!!! (read re-post) LIKE & FOLLOW me 👉 @Mike22332233 for further info

0 · Reply

judgeyoung2 Aug. 25 at 4:41 PM

$INBX woah

0 · Reply

MBWallingford Aug. 25 at 4:22 PM

$INBX some kind of rumor has to driving this. I bought high and averaged down. Given this is speculation I have a big position. The volume should be higher. Let’s see the day is not over.

0 · Reply

Dmnaz Aug. 25 at 4:14 PM

$INBX would like to see a bit more volume but this is running nicely

0 · Reply

Mongolikecandy Aug. 25 at 3:40 PM

$INBX Took a little breather for a few months now heading north again. Go baby go!

0 · Reply

judgeyoung2 Aug. 21 at 11:50 PM

$INBX that rumor back in April does make me think there’s a chance we wake up to an offer before the data but we’ll see

0 · Reply

Quantumup Aug. 21 at 12:19 PM

Stifel reiterated $INBX Buy-$325 after it recently hosted a series of investor meetings w/ Mark Lappe (Founder, CEO) & Kelly Deck (EVP, CFO). $BNTX $GMAB BGNE SNY CMTX IMNM PRTA PHMMF DCOY Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2090775723531219121?s=20

0 · Reply

justiceforb_85 Aug. 19 at 8:53 PM

$INBX nice to see this doing well.

0 · Reply

Terzman Aug. 19 at 8:34 PM

$INBX why would you even short this at this stage .. you would have to be masochistic

0 · Reply

rakesh_py Aug. 19 at 7:22 PM

$INBX i am Bullish on this, i hope moderna cancer medicine testing proxy might add some catelist for INBX. Not a recommendation. I have to check with Finantial Analyst.

0 · Reply

Market Cap	1.82B
Revenue (ttm)	1.30M
Net Income (ttm)	-140.06M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,773.85%
Debt to Equity Ratio	-3.33

Volume	241,400
Avg Vol	295,062
Day's Range	N/A - N/A
Shares Out	14.72M
Stochastic %K	82%
Beta	3.51
Analysts	Strong Sell
Price Target	$266.67